{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T23:36:04Z","timestamp":1769470564743,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,26]]},"DOI":"10.7759\/cureus.102308","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T13:08:39Z","timestamp":1769432919000},"source":"Crossref","is-referenced-by-count":0,"title":["Treatment of Acute Myeloid Leukemia in Elderly Patients With Azacitidine\u2013Venetoclax Combination in Developing Countries: A Single-Center Experience"],"prefix":"10.7759","author":[{"given":"Rim","family":"Chakara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aznag","family":"Mohamed Amine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abderrahim","family":"Raissi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-012-1137-3","article-title":"Acute myeloid leukemia in older adults","volume":"96","author":"Yanada M","year":"2012","unstructured":"Yanada M, Naoe T. Acute myeloid leukemia in older adults. Int J Hematol. 2012, 96:186-93. 10.1007\/s12185-012-1137-3","journal-title":"Int J Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis RM","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019, 36:70-87. 10.1016\/j.blre.2019.04.005","journal-title":"Blood Rev"},{"key":"ref3","unstructured":"Cancer Stat Facts. leukemia\u2014acute myeloid leukemia (AML). (2026). Accessed: January 4, 2026: https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61727-9","article-title":"Acute myeloid leukaemia in adults","volume":"381","author":"Ferrara F","year":"2013","unstructured":"Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet. 2013, 381:484-95. 10.1016\/S0140-6736(12)61727-9","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-604546","article-title":"Hematopoietic stem cell transplantation for patients with AML in first complete remission","volume":"127","author":"Cornelissen JJ","year":"2016","unstructured":"Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood. 2016, 127:62-70. 10.1182\/blood-2015-07-604546","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-604520","article-title":"An update of current treatments for adult acute myeloid leukemia","volume":"127","author":"Dombret H","year":"2016","unstructured":"Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016, 127:53-61. 10.1182\/blood-2015-08-604520","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian H","year":"2021","unstructured":"Kantarjian H, Kadia T, DiNardo C, et al.. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021, 11:41. 10.1038\/s41408-021-00425-3","journal-title":"Blood Cancer J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo CD","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, et al.. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020, 383:617-29. 10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000937","article-title":"Venetoclax for AML: changing the treatment paradigm","volume":"3","author":"Pollyea DA","year":"2019","unstructured":"Pollyea DA, Amaya M, Strati P, Konopleva MY. Venetoclax for AML: changing the treatment paradigm. Blood Adv. 2019, 3:4326-35. 10.1182\/bloodadvances.2019000937","journal-title":"Blood Adv"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo CD","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, et al.. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019, 133:7-17. 10.1182\/blood-2018-08-868752","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo CD","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A, et al.. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020, 135:791-803. 10.1182\/blood.2019003988","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33508","article-title":"Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia","volume":"127","author":"Rausch CR","year":"2021","unstructured":"Rausch CR, DiNardo CD, Maiti A, et al.. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer. 2021, 127:2489-99. 10.1002\/cncr.33508","journal-title":"Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-188088","article-title":"Outpatient low\u2011dose venetoclax plus azacitidine vs. intensive chemotherapy for newly diagnosed fit patients with acute myeloid leukemia in a limited\u2011resource setting","volume":"142","author":"Lopez\u2011Garcia YK","year":"2023","unstructured":"Lopez\u2011Garcia YK, De La Garza F, De la Rosa\u2011Flores GA, et al.. Outpatient low\u2011dose venetoclax plus azacitidine vs. intensive chemotherapy for newly diagnosed fit patients with acute myeloid leukemia in a limited\u2011resource setting. Blood. 2023, 142:1. 10.1182\/blood-2023-188088","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)01201-1","article-title":"Outcomes of azacitidine-venetoclax therapy in upfront and relapsed\/refractory AML: real-world experience from India","volume":"24","author":"Ghosh S","year":"2024","unstructured":"Ghosh S, Sinha S, Chatterjee S, et al.. Outcomes of azacitidine-venetoclax therapy in upfront and relapsed\/refractory AML: real-world experience from India. Clin Lymphoma Myeloma Leuk. 2024, 24:1. 10.1016\/S2152-2650(24)01201-1","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner H","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, et al.. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022, 140:1345-77. 10.1182\/blood.2022016867","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111232","article-title":"Single-institution experience of venetoclax combined with azacitidine in newly diagnosed acute myeloid leukemia patients","volume":"127","author":"Yu H","year":"2024","unstructured":"Yu H, Wang C, Lei Y, et al.. Single-institution experience of venetoclax combined with azacitidine in newly diagnosed acute myeloid leukemia patients. Int Immunopharmacol. 2024, 127:111232. 10.1016\/j.intimp.2023.111232","journal-title":"Int Immunopharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2024.100017","article-title":"Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS","volume":"1","author":"Othman J","year":"2024","unstructured":"Othman J, Lam HP, Leong S, et al.. Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS. Blood Neoplasia. 2024, 1:100017. 10.1016\/j.bneo.2024.100017","journal-title":"Blood Neoplasia"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139923","article-title":"First results from a nationwide prospective non-interventional study of venetoclax-based 1st line therapies in patients with AML - Revive Study","volume":"136","author":"Wolach O","year":"2020","unstructured":"Wolach O, Levi I, Canaani J, et al.. First results from a nationwide prospective non-interventional study of venetoclax-based 1st line therapies in patients with AML - Revive Study. Blood. 2020, 136:27\u20118. 10.1182\/blood-2020-139923","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147245","article-title":"Real world prospective observational multicenter trial of venetoclax-based therapy for patients with AML - Revive Study","volume":"9","author":"Wolach O","year":"2025","unstructured":"Wolach O, Levi I, Lavie D, et al.. Real world prospective observational multicenter trial of venetoclax-based therapy for patients with AML - Revive Study. Blood Adv. 2025, 9:1544-54. 10.1182\/blood-2021-147245","journal-title":"Blood Adv"},{"key":"ref20","unstructured":"Real-world use of venetoclax + azacitidine in elderly (\u226570 years) chemotherapy-ineligible untreated AML patients. a second level hospitals experience. (2024). Accessed: January 4, 2026: https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/421249\/carolina.villegas.da.ros.real-world.use.of.venetoclax.%2B...."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2024.09.658","article-title":"Clinical characteristics and outcome of patients receiving venetoclax-based regimens in Brazil: a real-world study","volume":"46","author":"Costa A","year":"2024","unstructured":"Costa A, Baptista RLR, Guaran\u00e1 M. Clinical characteristics and outcome of patients receiving venetoclax-based regimens in Brazil: a real-world study. Hematol Transfus Cell Ther. 2024, 46:S391. 10.1016\/j.htct.2024.09.658","journal-title":"Hematol Transfus Cell Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1177\/20406207251372770","article-title":"Real-world outcomes of azacitidine plus venetoclax in acute myeloid leukemia: a multicenter retrospective cohort study from Thailand","volume":"16","author":"Rattanathammethee T","year":"2025","unstructured":"Rattanathammethee T, Chanswangphuwana C, Silpsamrit P, et al.. Real-world outcomes of azacitidine plus venetoclax in acute myeloid leukemia: a multicenter retrospective cohort study from Thailand. Ther Adv Hematol. 2025, 16:20406207251372770. 10.1177\/20406207251372770","journal-title":"Ther Adv Hematol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-07126-y","article-title":"A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia","volume":"30","author":"Zhu LX","year":"2022","unstructured":"Zhu LX, Chen RR, Wang LL, et al.. A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia. Support Care Cancer. 2022, 30:7031-8. 10.1007\/s00520-022-07126-y","journal-title":"Support Care Cancer"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000043979","article-title":"Venetoclax combined with azacitidine in elderly acute myeloid leukemia: a retrospective comparison of 14-day vs 28-day dosing regimens","volume":"104","author":"Yu Z","year":"2025","unstructured":"Yu Z, Li S, Pei R, Lu Y, Wang Y, Yuan J. Venetoclax combined with azacitidine in elderly acute myeloid leukemia: a retrospective comparison of 14-day vs 28-day dosing regimens. Medicine (Baltimore). 2025, 104:e43979. 10.1097\/MD.0000000000043979","journal-title":"Medicine (Baltimore)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199315","article-title":"Infectious complications and antibiotic prophylaxis during induction therapy with venetoclax plus azacitidine for previously untreated AML: a real-world experience","volume":"144","author":"Brandwein J","year":"2024","unstructured":"Brandwein J, Liew E, Page D, Wang P. Infectious complications and antibiotic prophylaxis during induction therapy with venetoclax plus azacitidine for previously untreated AML: a real-world experience. Blood. 2024, 144:5971. 10.1182\/blood-2024-199315","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/450424-treatment-of-acute-myeloid-leukemia-in-elderly-patients-with-azacitidine-venetoclax-combination-in-developing-countries-a-single-center-experience","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T13:08:42Z","timestamp":1769432922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/450424-treatment-of-acute-myeloid-leukemia-in-elderly-patients-with-azacitidine-venetoclax-combination-in-developing-countries-a-single-center-experience"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.102308","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,26]]}}}